An update of a long-term denosumab (Xgeva) trial offers another bisphosphonate as an alternative to zoledronic acid (Zometa) that is more convenient, less toxic, and more effective in bone metastases. But oncologists need to perform an oral exam of patients with bone metastases before placing them on denosumab.
Industry Update: Agents Slow Disease Progression, Improve Daily Function in Metastatic Breast Cancer
Results from the GINECO group study demonstrate Afinitor’s ability to buy more time for patients while Xgeva makes everyday life less painful.
More than 700,000 biopsies are performed in the U.S. every year, but the technology has not always kept pace with cancer diagnosis and therapy. A new technique allows rapid and easy access to the
ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
Stephen Lutz, MD, talks about the evolution of the ASTRO guideline and how it answers vital questions for radiation oncologists.
Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies.
Early data from an ongoing randomized trials in the UK strongly suggest that denosumab might play a defined role in the future management of metastatic bone disease.
Complications of the bone remain a major clinical problem in oncology, resulting in significant morbidity and increased risk of death.
Osteoporosis in elderly cancer patients is an increasing problem, yet it remains under-recognized and under-managed. We commend Dr. Balducci for writing a comprehensive review of the bone complications associated with cancer and its treatment in the elderly.
Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients.
Bone renewal is essential for bone strength. During childhood and early adulthood, bone formation prevails over bone resorption, as bones increase in size and strength. Peak bone mass is achieved during the third decade in life, with a higher peak bone mass being protective against osteoporosis later in life. Bone loss is most prominent in women at menopause due to the effects of a natural decline in estrogen levels. However, bone mass begins to decrease with age, and bone loss is most prominent in women at menopause due to the effects of a natural decline in estrogen levels.